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Current vaccine and therapeutic delivery is largely needle-based, [1] but a number of
inherent risks and disadvantages to needle-based delivery have been recognized, such as the
need for cold storage of liquid formulations, [1, 2] the requirement of trained personnel for
administration, and reduced safety due to needle re-use and needle-based injuries. [3] To
address these limitations, vaccination and therapeutics administration through the skin
represents a promising alternative strategy, [4-6] and technologies promoting efficient
transcutaneous delivery of a variety of drugs and vaccines has become a significant focus of
recent research (reviewed in [7]). Recent work in this area has demonstrated the utility of
microneedle arrays for efficient and pain-free disruption of the stratum corneum (SC),
promoting transcutaneous delivery of a variety of bio-active materials. [8, 9] Microneedle
delivery is often achieved by coating dried water-soluble drug formulations directly on the
surfaces of solid microneedles. Parallel studies in the area of polyelectrolyte multilayer
(PEM) engineering have demonstrated the potential for simple and versatile materials
encapsulation into conformal thin films, providing robust control over materials release,
solid-state stabilization of environmentally-sensitive encapsulated materials, and nanometer-
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scale control over film structure and composition. [10-16] We recently reported the
construction of PEM films loaded with vaccine components prepared on flexible substrates
for transcutaneous vaccine delivery. [10] However, these planar multilayer patches require
prior SC disruption to permit entry of released cargos from the PEM films into the
epidermis. We hypothesized that combining the flexible and highly tunable nature of PEM
thin film coatings with microneedle substrates enabling direct entry of films into the viable
epidermis could provide a versatile platform for single-step transcutaneous delivery of a
broad range of drugs and drug carriers that is effective, generally applicable, inherently safe
and pain-free, and potentially cost effective.
In vitro delivery of plasmid DNA from PEMs has been demonstrated using multilayers that
deconstruct in aqueous conditions via parallel disassembly and degradation of the
constituent polymers. [17, 18] We show here that microneedle arrays coated with DNA-
carrying PEMs allows this concept to be translated to in vivo transfection in murine skin, an
approach of great interest for DNA vaccine delivery. Similarly, we show that biodegradable
poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs), ubiquitous in drug delivery, can be
embedded within microneedle PEM coatings, and subsequently deposited in the epidermis
following a brief application of microneedles to unmanipulated skin. Finally, we show that
multilayers combining these two diverse types of therapeutic cargos can be prepared for co-
delivery into skin. To our knowledge, this is the first report of functional coating deposition
onto microneedle arrays through the use of layer-by-layer (LbL) PEM self-assembly.
Furthermore, although transcutaneous plasmid DNA delivery has been demonstrated by
topical application to barrier disrupted skin [19, 20] and recently through application of
microneedles coated with dried formulations, [21] this is the first reported demonstration of
in situ DNA delivery from PEM films or PEM-coated microneedles to mediate in vivo gene
delivery and expression.
We first used laser micromachining to prepare poly(dimethylsiloxane) (PDMS) slabs with
arrays of tapered pyramidal or conical microscale cavities across their surface, to serve as
molds for polymer microneedle fabrication. Similar to prior reports, [22] PLGA pellets
placed over the molds were melted under vacuum, cooled, and separated from the PDMS
(Figure S1) to obtain arrays of microneedles each 250μm in diameter at their base and
900μm in height (Figures 1A, S2). Microneedles of similar dimensions have been shown to
produce negligible pain sensations in humans, while maintaining adequate structural
integrity to efficiently penetrate the SC. [23] To fabricate a biodegradable PEM coating
capable of controlled DNA release in vivo, we employed a hydrolytically degradable poly(β-
amino ester) (PBAE), designated polymer-1 (poly-1, Figure S3). [24] PBAEs have been
previously shown to be biocompatible and degradable, to build multilayers with DNA that
transfect cells in vitro, and to have adjuvant activity when co-delivered with DNA vaccines.
[18, 25, 26] Poly-1 in particular has been used recently by our group to fabricate LbL films
with controlled erosion and tunable drug release, [12, 27, 28] and by others to fabricate DNA-
releasing PEM films for potential gene delivery applications. [19, 29] To provide a uniform
initial surface charge density for PEM film growth on the PLGA microneedles, we first
deposited twenty bilayers of poly(4-styrene sulfonate) (SPS), a synthetic polyanion, and
protamine sulfate (PS), a mixture of four related biocompatible, highly cationic polypeptides
of approximately 30 amino acids (Figure S1). [30, 31] Onto this base film, PEMs were built
through the alternating adsorption of poly-1 and plasmid DNA (encoding firefly luciferase,
pLUC). Surface profilometry and UV absorbance indicated linear growth of (poly-1/plasmid
DNA) multilayers (∼0.5 ± 0.1 μg pDNA/cm2/bilayer) when deposited onto the (PS/SPS)
base-layer (Figure 1B). Confocal laser scanning microscopy (CLSM) was used to
qualitatively examine microneedles coated with Cy3-labeled pDNA PEMs. Microneedle
arrays coated in this way showed surface-localized fluorescence conformally coating each
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microneedle (Figures 1C and S4A), while control uncoated needles showed no background
fluorescence (data not shown).
We next tested whether a similar approach could be used to incorporate biodegradable
polymer NPs into microneedle coatings. Lipid-coated PLGA NPs (244 nm in diameter, PDI
0.15) bearing a phospholipid surface layer composed of the zwitterionic lipid DOPC, the
anionic lipid DOPG, and containing a lipophilic tracer dye (DiI or DiD) were prepared using
an emulsion/solvent evaporation process we recently described. [32] Microneedles were
primed with a (PS/SPS) base layer as before, and then alternating layers of poly-1 and
PLGA NPs were deposited onto the arrays via spray LbL multilayer self-assembly (Figure
S1). [33] CLSM (Figures 1D and S4B) and SEM (Figure 1E) imaging of the nanoparticle
PEM-coated arrays revealed conformal coatings on the microneedles, similar to the results
seen with (poly-1/DNA) films. Four (poly-1/NP) bilayers produced a coating approximately
2 μm thick as measured by profilometry. In addition, serial deposition of (poly-1/pLUC)
followed by (poly-1/NP) bilayers on the same microneedle array permitted the creation of
films carrying both functional components (Figures 1F and S4C). Thus, PEM-coated
microneedles have the potential to act as multifunctional delivery platforms, carrying cargos
with diverse physical properties.
We next analyzed the penetration of microneedle arrays into the dorsal ear skin of C57Bl/6
mice or C57Bl/6-MHC II-GFP mice, transgenic animals expressing green fluorescent
protein (GFP) fused to all class II major histocompatibility complex (MHC) molecules. [34]
The MHC II-GFP fusion protein provided an in situ fluorescence marker for the viable
epidermis in skin samples from these mice, as fluorescent epidermal MHC II+ Langerhans
cells (LCs) are readily detected by CLSM in mouse auricular skin. [12] Prior reports have
demonstrated that microneedles prepared from biodegradable polymers with suitable elastic
moduli and needle geometries can penetrate human cadaver skin. [23] To confirm that our
PLGA arrays could similarly penetrate murine skin, uncoated microneedles were applied to
dorsal ear skin. Trypan blue staining revealed efficient and consistent penetration of PLGA
microneedle arrays through the SC; [8] light microscopic inspection of arrays before/after
application showed some buckling/bending but little breakage of the needle tips (Figures 2A
and S5). CLSM imaging of ear skin from MHC II-GFP transgenic mice showed that
microneedles readily penetrated into the viable epidermis where LCs were colocalized
within the same z-plane (Figure S6). To determine if PEM-coated microneedle arrays could
deliver pDNA and/or NP cargos into the skin, we prepared PEM-coated microneedles
carrying Cy3-labeled pLUC DNA (Cy3-pLUC) or DiI-labeled PLGA NPs (DiI-PLGA NPs).
These PEM-coated arrays were applied to the ears of live anesthesized MHC II-GFP mice
for 1 min, 5 min or 24 hrs, and then both the freshly explanted ear skin and the applied
microneedles were examined by CLSM. Interestingly, the cargo delivery properties of these
two types of microneedle coatings were quite distinct. Microneedles carrying (poly-1/
pDNA) films examined before and after application to skin showed very little loss of DNA
from the needle surfaces after applications of 1 or 5 min (Figure 2B and Figures S7A, B, D,
and data not shown), and little detectable transferred DNA in the epidermis (Figures 2D and
S8A), but arrays applied to skin for 24 hours led to nearly complete loss of pDNA from the
microneedles (Figure 2B and Figures S7C, D) with a corresponding pronounced
accumulation of DNA in the skin at depths colocalizing with LCs (Figure 2E and S8B). In
contrast, microneedles carrying 4 bilayers of spray-deposited (poly-1/PLGA NP) films
showed immediate transfer of NPs into the epidermis and coincident loss of NP signal from
the microneedles themselves following even a 5 minute application on the skin (Figures 2C,
2F, S9, S10). These disparate results suggest that plasmid DNA-containing PEM thin films
remained intact upon microneedle penetration and subsequently release DNA over a period
of 24 hours, while PLGA NP-containing PEM thin films are likely deposited in the skin
concomitantly with microneedle insertion. It is anticipated that pDNA undergoes some
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degree of interpenetration during incorporation in PEMs, consistent with other polyion
species. This would lead to molecular entanglements that would not be present in the
nanoparticle thin films and could account for the relative ease of removal of these films once
inserted into the skin. Thus both PEM multilayer architecture and the nature of the
encapsulated components are parameters controlling the delivery properties of PEM-coated
microneedles. Notably, arrays coated first with (poly-1/pLUC) followed by 4 bilayers of
spray-deposited (poly-1/PLGA NPs) co-delivered DNA and PLGA NPs to the skin of live
mice after a 24-hr application (Figures 2G and S11).
Although murine and human skin exhibit a number of structural differences, preclinical
mouse studies of transcutaneous vaccine delivery have been remarkably predictive of
clinical trial results. [6] In addition, the mouse model permits a detailed functional analysis
of biological responses to delivered pDNA or NPs. In order to further evaluate the potential
of PEM-coated microneedle arrays for transcutaneous DNA delivery, we assessed the ability
of (poly-1/pLUC)-coated PLGA microneedles to transfect cells in vivo. PEM-coated
microneedles were applied to the dorsal ear skin of C57BL/6 mice, and in vivo transfection
was quantified over time using whole animal bioluminescence imaging to detect luciferase
expression. Mice were treated by application of a 24 bilayer (poly-1/pLUC)-coated
microneedle array to ear skin for 5 minutes (Figure 3A), or a 1- (Figure 3B), 5- (Figure 3C)
or 24-bilayer (Figure 3D) array for 24 hrs. Bioluminescence was then monitored in vivo for
7 days. Successful in vivo transfection and expression of firefly luciferase in the ear skin was
detected for both 5 minute and 24 hr application times, despite the low level of pDNA
detected in skin for the former (Figure 3E). In both cases, luciferase expression was detected
for over a week, though pLUC-coated microneedles applied for 24 hours resulted in an
increase in the intensity of luciferase expression, as expected from the CLSM results
described above. Additionally, the iterative nature of LbL film construction is amenable to
robust dosage control. Application of microneedle arrays coated with 1, 5, or 24 bilayers of
(poly-1/pLUC) for 24 hours gave luciferase expression levels spanning an order of
magnitude (Figure 3F).
In conclusion, as a first step towards the design of a general materials platform for
transcutaneous DNA and therapeutic NP delivery, we have demonstrated for the first time
the application of LbL self-assembly for the deposition of functional coatings on
microneedle arrays. We have shown the versatility of this approach, engineering PEM films
containing pDNA and/or degradable polymer NPs, and demonstrating their utility for
delivery into the viable epidermis through microneedle application. Finally, we have shown
for the first time to our knowledge, successful in vivo transfection via DNA released from
microneedle-supported PEM films. These findings suggest the potential utility of these
materials for DNA vaccine delivery and gene therapy, as well as the possibility of co-
delivery of therapeutic-loaded degradable polymer NPs for sustained and controlled release
of encapsulated materials in vivo.
Experimental
PLGA Microneedle Fabrication
PDMS molds (Sylgard 184, Dow Corning) were fabricated by laser ablation using a Clark-
MXR, CPA-2010 micromachining system. PLGA pellets (50:50wt lactide: glycolide, 46
kDa, Lakeshore Biomaterials) were melted over the molds under vacuum (-25 in. Hg) at
145°C for 40 minutes, and then cooled at -20°C before separating the cast microneedle
arrays. Arrays were characterized using a JEOL 6700F FEG-SEM.
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PLGA Nanoparticle Preparation
PLGA nanoparticles were prepared as previously described. [32] Briefly, PLGA (30 mg),
DOPC/DOPG lipids (4:1 mol ratio, 5 mg, Avanti Polar Lipids), and DiI or DiD (6.4 ng,
Invitrogen) were co-dissolved in dichloromethane (1 mL). PBS (200 μL) was added, the
emulsion was sonicated (7W, 1 minutes) using a Microson cell disruptor, added to Milli-Q
(MQ) water (4 mL), and sonicated again (12W, 5 minutes), followed by incubation for 12
hours at 25°C. The resulting particles were purified on a sucrose gradient and analyzed using
a BIC 90+ light scattering instrument (Brookhaven Instruments Corp).
Polymer Multilayer Film Preparation
All LbL films were assembled using a Carl Ziess HMS DS50 slide stainer. Films were
constructed on silicon wafers, quartz slides, and PLGA microneedle arrays following
treatment with O2 plasma. To build (PS/SPS) baselayers, substrates were dipped
alternatively into PS (2 mg/mL, 100 M NaOAc, Sigma-Aldrich) and SPS (5 mM, 20 mM NaCl,
Sigma-Aldrich) solutions for 10 minutes separated by two sequential 1 minute rinses in MQ
water. [30] (Poly-1/pLUC) multilayers were deposited similarly, alternating 5 minute dips in
Poly-1 (2 mg/mL in 100 mM NaOAc, synthesized according to previous literature [24, 26])
and pLUC (1 mg/mL, 100 mM NaOAc, a gift from Dr. Daniel Barouch, Beth Israel
Deaconess Medical Center) solutions separated by two sequential rinsing steps in NaOAc
(100 mM, pH 5.0). Fluorescent pLUC was prepared using Cy3 Label-IT reagent (Mirus Bio
Corporation). All solutions (except pLUC) were adjusted to pH 5.0 and filtered (0.2 μm)
prior to dipping.
Particle Multilayer Film Preparation
Films were assembled using a previously described spray LbL technique. [33] Briefly,
microneedle arrays were coated with atomized spray solutions using modified air-brushes.
Poly-1 (2 mg/mL, 100 mM NaOAc) and PLGA NP (20 mg/mL in MQ water) solutions were
sprayed alternatively for 3 seconds (0.2 mL/s, 15 cm range) separated by 6 second rinses
with NaOAc (100 mM). Film thickness was measured using a Tencor P-16 surface
profilometer. Film delivery was characterized through CLSM imaging of microneedle arrays
using a Zeiss LSM 510 and data analysis using Image J. [35]
In Vivo Transcutaneous Delivery
Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state,
local, and NIH guidelines for animal care. Microneedle application experiments were
performed on anesthetized C57BL/6 mice (Jackson Laboratories) and MHC II-GFP
transgenic mice (a gift from Prof. Hidde Ploegh) [34]. Ears were rinsed briefly with PBS on
the dorsal side and dried before application of microneedle arrays by gentle pressure.
Microneedles were then removed or secured in place using Nexcare medical tape (3M).
Mice were sacrificed and excised ears were stained with trypan blue before imaging for
needle penetration. Ears collected from mice treated with Cy3-pLUC- and/or DiI-PLGA-
NP-coated microneedle arrays were mounted on glass slides and imaged by CLSM.
Transfection in mice treated with pLUC-coated arrays was measured using an IVIS
Spectrum 200 (Caliper Lifesciences) to detect bioluminescence, following IP injection of
luciferin.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(A) SEM micrograph of uncoated PLGA microneedle arrays of pyramidal geometry (scale -
500μm). (B) Film growth (left axis) and absorbance (right axis) for (Poly-1/pLUC)n
multilayers assembled on silicon/quartz substrates bearing a (PS/SPS)20 initiating layer
(black bar - (PS/SPS)20, grey bar - (Poly-1/pLUC)n, dashed line – Ab-260 nm). (C, D)
Representative confocal micrographs showing a (C) (PS/SPS)20-(Poly-1/Cy3-pLUC)24
coated microneedle and a (D) (PS/SPS)20-(Poly-1/DiI-PLGA NP)4 coated microneedle (left
– transverse section, right – lateral sections, 200μm intervals, scale - 200 μm). (E) SEM
micrograph showing a (PS/SPS)20-(Poly-1/PLGA NP)4 coated microneedle array (scale -
50μm). (F) Representative confocal micrographs showing a (PS/SPS)20-(Poly-1/Cy3-
pLUC)24-(Poly-1/DiD-PLGA NP)4 co-coated microneedle (transverse and lateral sections,
left – Cy3-pLUC, right – DiD-PLGA NP, 200μm intervals, scale - 200 μm).
DeMuth et al. Page 8
Adv Mater. Author manuscript; available in PMC 2011 May 16.
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
Figure 2.
(A) Optical micrograph of ear skin showing microneedle penetration pattern stained using
trypan blue (scale – 100μm). (B) Representative confocal z-stacks and quantification (n = 6)
of (PS/SPS)20-(Poly-1/Cy3-pLUC)24-coated microneedle arrays (left – brightfield, middle –
before application, right – after 24 hour application, 200μm interval, scale - 200μm). (C)
Representative confocal z-stacks and quantification (n = 6) of (PS/SPS)20-(Poly-1/DiI-
PLGA-NP)4 coated microneedle arrays (left – brightfield, middle – before application, right
– after 5 minute application, 200μm interval, scale – 200μm). Representative confocal
micrographs (1 – MHC-GFP II, 2 – Cy3-pLUC, 3 – DiI/D-PLGA NP, 4 – overlay, scale –
200μm) showing dorsal ear skin following (D) 5 minute and (E) 24 hour application of a
(PS/SPS)20-(Poly-1/Cy3-pLUC)24 coated microneedle array, (F) 5 minute (PS/SPS)20-
(Poly-1/DiI-PLGA-NP)4 coated microneedle application, and (G) 24 hour (PS/SPS)20-
(Poly-1/Cy3-pLUC)24-(Poly-1/DiD-PLGA NP)4 coated microneedle application.
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Figure 3.
In vivo bioluminescent signal observed in C57BL/6 mice (n = 3) following treatment with a
(PS/SPS)20-(Poly-1/pLUC)n – coated microneedle array to the right ear (denoted by arrow):
(A) 24 bilayers for 5 minutes, (B) 1 bilayer for 24 hours, (C) 5 bilayers for 24 hours, and (D)
24 bilayers for 24 hours. The bioluminescent results following treatment are summarize in
(E, F) for 7 days together with the negative control signal (denoted C) collected from the
untreated ear, with (E) demonstrating the effect of application time and (F) showing the
result of increasing pLUC dosage.
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